The U.S. hereditary cancer testing market was estimated at USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 13.32% from 2025 to 2033. The U.S. hereditary cancer testing market is driven by growing awareness of inherited cancer risks, with 5-10% of cancers linked to germline mutations. Rising adoption of guideline-based screening from NCCN and ACOG, coupled with FDA authorization of panels, is boosting clinician confidence and payer coverage. Technological advancements such as integration of DNA/RNA sequencing, digital screening tools, and combined germline-somatic profiling are expanding clinical utility. Increasing partnerships, patient education initiatives, and insurance support are further accelerating access, positioning hereditary testing as a cornerstone of precision oncology.
In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.
This product will be delivered within 1-3 business days.
In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.
U.S. Hereditary Cancer Testing Market Report Segmentation
This report forecasts revenue growth at, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the hereditary cancer testing market report on the basis of test type, technology, cancer, andend-use:Cancer Outlook (Revenue, USD Million, 2021-2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Ovarian Cancer
- Prostate Cancer
- Stomach/Gastric Cancer
- Melanoma
- Sarcoma
- Uterine Cancer
- Pancreatic Cancer
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Cytogenetic
- Biochemical
- Molecular Testing
Test Type Outlook (Revenue, USD Million, 2021-2033)
- Predictive Testing
- Diagnostic Testing
End-use Outlook (Revenue, USD Million, 2021-2033)
- Diagnostic Centers
- Hospitals
- Clinics
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Hereditary Cancer Testing Market Variables, Trends & Scope
Chapter 4. U.S. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis
Chapter 5. U.S. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis
Chapter 6. U.S. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis
Chapter 7. U.S. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Hereditary Cancer Testing market report include:- Myriad Genetics,
- Invitae Corporation
- Bio-Rad Laboratories
- CSL Ltd
- Qiagen NV
- Danaher Corporation
- Thermo Fisher Scientific
- Abbott Laboratories
- EUROFINS SCIENTIFIC
- F. HOFFMANN-LA ROCHE LTD
- Illumina, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.93 Billion |
| Forecasted Market Value ( USD | $ 5.76 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
